JP2021531273A5 - - Google Patents
Info
- Publication number
- JP2021531273A5 JP2021531273A5 JP2021502476A JP2021502476A JP2021531273A5 JP 2021531273 A5 JP2021531273 A5 JP 2021531273A5 JP 2021502476 A JP2021502476 A JP 2021502476A JP 2021502476 A JP2021502476 A JP 2021502476A JP 2021531273 A5 JP2021531273 A5 JP 2021531273A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- xrpd
- solid form
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024063946A JP2024083556A (ja) | 2018-07-18 | 2024-04-11 | アゾロピリミジン化合物の固体形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862700064P | 2018-07-18 | 2018-07-18 | |
| US62/700,064 | 2018-07-18 | ||
| PCT/US2019/042226 WO2020018680A1 (en) | 2018-07-18 | 2019-07-17 | Solid forms of an azolopyrimidine compound |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024063946A Division JP2024083556A (ja) | 2018-07-18 | 2024-04-11 | アゾロピリミジン化合物の固体形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531273A JP2021531273A (ja) | 2021-11-18 |
| JP2021531273A5 true JP2021531273A5 (https=) | 2022-07-26 |
| JP7522720B2 JP7522720B2 (ja) | 2024-07-25 |
Family
ID=69164033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502476A Active JP7522720B2 (ja) | 2018-07-18 | 2019-07-17 | アゾロピリミジン化合物の固体形態 |
| JP2024063946A Withdrawn JP2024083556A (ja) | 2018-07-18 | 2024-04-11 | アゾロピリミジン化合物の固体形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024063946A Withdrawn JP2024083556A (ja) | 2018-07-18 | 2024-04-11 | アゾロピリミジン化合物の固体形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11993584B2 (https=) |
| EP (1) | EP3823614A4 (https=) |
| JP (2) | JP7522720B2 (https=) |
| KR (1) | KR102826213B1 (https=) |
| CN (1) | CN113015523B (https=) |
| AU (1) | AU2019306582B2 (https=) |
| CA (1) | CA3106366A1 (https=) |
| MY (1) | MY205549A (https=) |
| PH (1) | PH12021550084A1 (https=) |
| SG (1) | SG11202100267TA (https=) |
| TW (1) | TWI835821B (https=) |
| WO (1) | WO2020018680A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113795267A (zh) | 2019-03-12 | 2021-12-14 | 艾库斯生物科学有限公司 | 致癌基因驱动的癌症的治疗 |
| WO2020205527A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| CN119768155A (zh) | 2022-09-14 | 2025-04-04 | 艾库斯生物科学有限公司 | 依曲地南的分散体 |
| WO2024097736A1 (en) | 2022-11-02 | 2024-05-10 | Arcus Biosciences, Inc. | Processes for preparing azolopyrimidine compounds |
| WO2025193759A1 (en) | 2024-03-12 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of an azolopyrimidine compound |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474599A (en) | 1982-07-14 | 1984-10-02 | The Dow Chemical Company | 1-(Pyridyl)-1H-1,2,3-triazole derivatives, and use as herbicidal agents |
| DE60223720T2 (de) * | 2001-12-18 | 2008-10-30 | Merck & Co., Inc. | Heteroaryl-substituierte pyrazol-modulatoren des metabotropen glutamatrezeptors-5 |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP2379075A4 (en) | 2008-12-16 | 2012-05-30 | Merck Sharp & Dohme | TRIAZOL DERIVATIVES FOR THE TREATMENT OF ALZHEIMER DISEASE |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2014048065A1 (en) * | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
| AU2014291142B2 (en) | 2013-07-17 | 2018-10-11 | Otsuka Pharmaceutical Co., Ltd. | Cyanotriazole compounds |
| HUE064141T2 (hu) | 2017-01-20 | 2024-02-28 | Arcus Biosciences Inc | Azolopirimidin rákkal összefüggõ rendellenességek kezelésére |
| CA3090922A1 (en) | 2018-02-16 | 2019-08-22 | Arcus Biosciences, Inc. | Dosing with an azolopyrimidine compound |
| CN113795267A (zh) | 2019-03-12 | 2021-12-14 | 艾库斯生物科学有限公司 | 致癌基因驱动的癌症的治疗 |
| WO2020205527A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| TWI855088B (zh) | 2019-06-06 | 2024-09-11 | 美商阿克思生物科學有限公司 | 製備胺基嘧啶化合物的方法 |
-
2019
- 2019-07-17 EP EP19838123.8A patent/EP3823614A4/en active Pending
- 2019-07-17 CN CN201980058983.5A patent/CN113015523B/zh active Active
- 2019-07-17 SG SG11202100267TA patent/SG11202100267TA/en unknown
- 2019-07-17 JP JP2021502476A patent/JP7522720B2/ja active Active
- 2019-07-17 CA CA3106366A patent/CA3106366A1/en active Pending
- 2019-07-17 AU AU2019306582A patent/AU2019306582B2/en active Active
- 2019-07-17 US US17/260,847 patent/US11993584B2/en active Active
- 2019-07-17 KR KR1020217004714A patent/KR102826213B1/ko active Active
- 2019-07-17 WO PCT/US2019/042226 patent/WO2020018680A1/en not_active Ceased
- 2019-07-17 MY MYPI2021000254A patent/MY205549A/en unknown
- 2019-07-18 TW TW108125369A patent/TWI835821B/zh active
-
2021
- 2021-01-13 PH PH12021550084A patent/PH12021550084A1/en unknown
-
2024
- 2024-04-11 JP JP2024063946A patent/JP2024083556A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021531273A5 (https=) | ||
| JP2025023997A (ja) | Ｆａｋ阻害剤およびその併用薬物 | |
| JP2023530456A5 (https=) | ||
| JP2015509537A5 (https=) | ||
| RU2014151565A (ru) | Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида | |
| CN101878218A (zh) | 埃克替尼盐酸盐及其制备方法、晶型、药物组合物和用途 | |
| JP2020521754A5 (https=) | ||
| KR102731401B1 (ko) | 키나아제 억제제로 사용되는 화합물 및 이의 응용 | |
| JP2016513704A5 (https=) | ||
| JP6894917B2 (ja) | ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用 | |
| CA2862704C (en) | Ribonucleotide reductase inhibitors and methods of use | |
| JP2022507267A5 (https=) | ||
| JP2008528466A5 (https=) | ||
| KR102142796B1 (ko) | 피리디닐아미노피리미딘 유도체의 염, 그의 제조 방법, 및 그의 용도 | |
| JP7245918B2 (ja) | サルササポゲニン構造に基づく誘導体、医薬組成物及びその使用 | |
| CN110396088A (zh) | Hpk1激酶抑制剂、制备方法及其应用 | |
| AU2022380979A1 (en) | Pparg inverse agonists and uses thereof | |
| JP2017507175A5 (https=) | ||
| HRP20211151T1 (hr) | Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama | |
| CN118119615A (zh) | Rho相关蛋白激酶抑制剂或其溶剂合物的固体形式及其制备方法和用途 | |
| CN107935944B (zh) | 具有抗肿瘤活性双芳基脲喹喔啉衍生物及其合成方法 | |
| AU2006216266A2 (en) | Quinazoline derivative having tyrosine kinase inhibitory activity | |
| CN105254699B (zh) | 4‑(4’‑三氟甲基)苯基‑2‑去氢表雄酮‑17’‑腙噻唑及其制备方法和用途 | |
| EP2029584A2 (en) | 2-[3h-thiazol-2-ylidinemethyl]pyridines and related compounds and their use | |
| JP2021522348A5 (https=) |